Dyadic International Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Dyadic InternationalDer Gewinn des Unternehmens wird voraussichtlich um 14.3% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 30.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-14.3%

Wachstumsrate der Gewinne

-6.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	30.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Dyadic International (NASDAQ:DYAI) In A Good Position To Deliver On Growth Plans?

Mar 14

Is Dyadic International (NASDAQ:DYAI) In A Good Position To Invest In Growth?

Oct 28

Here's Why We're Watching Dyadic International's (NASDAQ:DYAI) Cash Burn Situation

Jun 21

We're Hopeful That Dyadic International (NASDAQ:DYAI) Will Use Its Cash Wisely

Oct 05

Dyadic collaborates with Syngene International to develop a COVID-19 vaccine candidate

May 26

We're Not Very Worried About Dyadic International's (NASDAQ:DYAI) Cash Burn Rate

May 03

Dyadic International's (NASDAQ:DYAI) Wonderful 318% Share Price Increase Shows How Capitalism Can Build Wealth

Feb 22

Dyadic International (NASDAQ:DYAI) Is In A Good Position To Deliver On Growth Plans

Jan 18

Do Insiders Own Lots Of Shares In Dyadic International, Inc. (NASDAQ:DYAI)?

Dec 10

Dyadic International reports Q3 results

Nov 12

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:DYAI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	6	-11	N/A	N/A	1
12/31/2025	6	-11	N/A	N/A	1
12/31/2024	4	-8	N/A	N/A	1
3/31/2024	2	-8	-6	-6	N/A
12/31/2023	3	-7	-7	-7	N/A
9/30/2023	3	-7	-7	-7	N/A
6/30/2023	3	-7	-7	-7	N/A
3/31/2023	3	-8	-7	-7	N/A
12/31/2022	3	-10	-8	-8	N/A
9/30/2022	2	-12	-9	-9	N/A
6/30/2022	2	-12	-12	-12	N/A
3/31/2022	3	-12	-12	-12	N/A
12/31/2021	2	-13	-11	-11	N/A
9/30/2021	2	-11	-10	-10	N/A
6/30/2021	2	-12	-7	-7	N/A
3/31/2021	2	-10	-6	-6	N/A
12/31/2020	2	-9	-7	-7	N/A
9/30/2020	2	-9	-7	-7	N/A
6/30/2020	2	-8	-7	-7	N/A
3/31/2020	2	-8	-6	-6	N/A
12/31/2019	2	-8	-6	-6	N/A
9/30/2019	2	-7	-6	-6	N/A
6/30/2019	2	-7	-5	-5	N/A
3/31/2019	2	-6	-5	-5	N/A
12/31/2018	1	-6	-4	-4	N/A
9/30/2018	1	-7	-4	-4	N/A
6/30/2018	1	-7	-5	-5	N/A
3/31/2018	1	-6	-2	-2	N/A
12/31/2017	1	-2	N/A	-2	N/A
9/30/2017	1	-3	N/A	-2	N/A
6/30/2017	1	-2	N/A	-5	N/A
3/31/2017	1	-1	N/A	-5	N/A
12/31/2016	1	-4	N/A	-6	N/A
9/30/2016	0	-2	N/A	-7	N/A
6/30/2016	0	0	N/A	-2	N/A
3/31/2016	0	-2	N/A	-2	N/A
12/31/2015	0	-1	N/A	-1	N/A
9/30/2015	0	-2	N/A	1	N/A
6/30/2015	-6	-4	N/A	-1	N/A
3/31/2015	-3	-5	N/A	-5	N/A
12/31/2014	0	-5	N/A	-6	N/A
9/30/2014	4	-5	N/A	-5	N/A
6/30/2014	14	-6	N/A	-2	N/A
3/31/2014	18	-1	N/A	3	N/A
12/31/2013	17	0	N/A	5	N/A
9/30/2013	16	-1	N/A	6	N/A
6/30/2013	15	0	N/A	5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DYAI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: DYAI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: DYAI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: DYAIDie Einnahmen des Unternehmens (30.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: DYAIDie Einnahmen des Unternehmens (30.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von DYAI in 3 Jahren voraussichtlich hoch sein wird

Dyadic International Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 17%

Consensus EPS estimates fall by 159%

Consensus revenue estimates increase by 25%

Consensus revenue estimates increase by 74%

Consensus forecasts updated

Consensus revenue estimates fall by 53%

Recent updates

Founder notifies of intention to sell stock

New minor risk - Share price stability

Consensus revenue estimates decrease by 17%

First quarter 2024 earnings released: US$0.07 loss per share (vs US$0.033 loss in 1Q 2023)

Dyadic International, Inc. to Report Q1, 2024 Results on May 14, 2024

Dyadic International, Inc., Annual General Meeting, Jun 11, 2024

Consensus EPS estimates fall by 159%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dyadic International, Inc. Announces Management Changes

Dyadic International, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Dyadic International, Inc. Announces Top-Line Results from Its Successful Phase 1 Clinical Trial for A First-In-Human Filamentous Fungal-Based Vaccine Candidate

New minor risk - Profitability

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates increase by 25%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Dyadic International, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Dyadic International, Inc Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate

Consensus revenue estimates increase by 74%

First quarter 2023 earnings released: US$0.033 loss per share (vs US$0.088 loss in 1Q 2022)

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Is Dyadic International (NASDAQ:DYAI) In A Good Position To Deliver On Growth Plans?

Dyadic International, Inc. Initiates Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

An unknown buyer acquired 1.99% stake in Alphazyme LLC from Dyadic International, Inc. (NasdaqCM:DYAI) for $1.27 million.

Consensus forecasts updated

Insufficient new directors

Consensus revenue estimates fall by 53%

Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for Dyai-100 Covid-19 Recombinant Protein Rbd Booster Vaccine Candidate

Is Dyadic International (NASDAQ:DYAI) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 31%

Forecast to breakeven in 2023

Dyadic International, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Here's Why We're Watching Dyadic International's (NASDAQ:DYAI) Cash Burn Situation

Consensus forecasts updated

Price target decreased to US$7.50

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Dyadic International, Inc. Announces Successful Toxicology Data Published in Toxicologic Pathology

Insufficient new directors

Dyadic International, Inc. Announces Executive Changes

Consensus revenue estimates fall by 42%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Dyadic International, Inc. Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

Dyadic International, Inc. Announces A National Institute for Innovation in Manufacturing Biopharmaceuticals Coronavirus Grant Under the White House’s American Rescue Plan

Forecast to breakeven in 2023

Price target decreased to US$8.50

Third quarter 2021 earnings released: US$0.061 loss per share (vs US$0.091 loss in 3Q 2020)

We're Hopeful That Dyadic International (NASDAQ:DYAI) Will Use Its Cash Wisely

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.097 loss in 2Q 2020)

Dyadic International, Inc.(NasdaqCM:DYAI) dropped from Russell 3000E Value Index

Chief Financial Officer recently bought US$59k worth of stock

Dyadic collaborates with Syngene International to develop a COVID-19 vaccine candidate

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.081 loss in 1Q 2020)

We're Not Very Worried About Dyadic International's (NASDAQ:DYAI) Cash Burn Rate

Consensus forecasts updated

Full year 2020 earnings released: US$0.34 loss per share (vs US$0.31 loss in FY 2019)

Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100

Dyadic International's (NASDAQ:DYAI) Wonderful 318% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day high: US$6.79

Independent Director exercised options to buy US$290k worth of stock.

Dyadic International, Inc. Enters Collaboration with Turtle Tree Scientific

Dyadic International (NASDAQ:DYAI) Is In A Good Position To Deliver On Growth Plans

Dyadic International, Inc. Appoints Patrick Lucy to its Board of Directors

New 90-day low: US$5.57

Do Insiders Own Lots Of Shares In Dyadic International, Inc. (NASDAQ:DYAI)?

Third quarter 2020 earnings released: US$0.091 loss per share

Earnings beat expectations, revenue disappoints

Dyadic International reports Q3 results

Dyadic International, Inc. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day low: US$6.85